Evidence map›Paper›PMID 25681554›Full record

ArticleJournal of hepatology2015

Pharmacological chaperone therapies: Can aldehyde dehydrogenase activator make us healthier?

Laurent Dollé, Bin Gao

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Role of ALDH2 in Hepatic Disorders: Gene Polymorphism and Disease Pathogenesis.Journal of clinical and translational hepatology · 2021
    Review
  6. Aldehyde Dehydrogenase, Liver Disease and Cancer.International journal of biological sciences · 2020
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Laurent DolléLaboratory of Liver Cell Biology, Department of Biomedical Sciences, Faculty of Medicine and Pharmacy, Free University Brussels (VUB), Brussels, Belgium. Electronic address: ldolle@vub.ac.be.
Bin GaoLaboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: bgao@mail.nih.gov.

Funding

Pathogenesis and Novel Therapeutic Targets of Steatotic Liver Disease and CancerZIAAA000369 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI GAO, BIN · 2009 to 2025
$23.4M
Molecular mechanisms of liver injury, repair, and immunityZIAAA000368 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI GAO, BIN · 2009 to 2023
$16.1M
Intramural NIH HHS
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Aldehyde DehydrogenaseAnimalsBenzamidesBenzodioxolesFatty Liver, AlcoholicMaleAldehyde DehydrogenaseBenzamidesBenzodioxolesAcetaldehydeAlda-1ALDH2Pharmacological chaperone

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.